Renata Couto
Head of Investor Relations
Replay available
Afya (NASDAQ:AFYA) Q1 2020 earnings call, held 2020-05-29. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/afya-limited-afya-q1-2020-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Good morning, ladies and gentlemen, and welcome to AFIA's first quarter 2020 earnings conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. As a reminder, this call will be recorded. I would now like to introduce your host for today's conference, Renata Couto, AFIA's head of IR. You may begin.
0:24 Thank you, and good morning, everyone. Thank you for joining us for AFCA's first quarter 2020 conference call. With me on the call today is our CEO, Virgílio Gibbon, Luis Andre Blanco, our CFO, and Julio de Angeli, our VP of Innovation and Continuum Medical Education. During today's presentation, our executives will make forward-looking statements. Forward-looking statements generally relate to future events or Future Financial or Operating Performance and involves known and unknown risks, uncertainties, and other factors that may cause or actual results to differ materially from those contemplated by these forward-looking statements.
1:14 Forward-looking statements in this presentation include but are not limited to statements related to our business and financial performance. Expectations and Guidance for future periods or expectations regarding our strategic product initiatives and the related benefits and our expectations regarding the market as well as the potential impact from COVID-19. This week includes those more fully described on our filing with the Curious and Exchange Commission. The forward-looking statement in this presentation are based on the information available to us as of the date hereof.
1:59 You should not rely on them as predictions of future events and we disclaim any obligation to update any forward-looking statements except as required by law. In addition, management may refer non-IFRS financial measures on this call. The non-IFRS financial measures are not intended to be considered in the isolation or as a substitute for the bills prepared in accordance with IFRS. We have provided a reconciliation of these non-IFRS financial measures to the most directly compared IFRS financial measures in this presentation. Let me now turn the call over to Virgílio Gibbon. After you.
2:46 Thank you, Renata, and thanks, everyone, for joining us today for Access for Squadron 2020 Learning Conference Call. First, let me say that I hope everyone is in good health and safe during this global crisis. Before we start, I would like to acknowledge and thank all frontline workers who are facing this global crisis. We are fortunate that, as a business, we have been able to help by providing free costs at this time to assist hospitals, I also want to thank our employees and professors who made it possible within one week to move 100% of our on-site classes to our online platform. The feedback from students, professors, and physicians could not be better.
3:34 They are all very satisfied with the effectiveness of our online operations. While the environment continues to evolve quickly, our teams are managing our priorities and business very well. Moving now to page number five. I'm very pleased to report a strong first quarter 2020 results, continuing the positive trend of 2019, and also reflecting the successful execution of our strategic initiatives. We are seeing the benefits from the synergies captured from the integration of the acquisitions completed over the past two years. and continue to deliver the combination of our strong and predictable world with high profitability and health cash generation. Our balance sheet position is very strong with more than 1.3 billion reais in cash.
4:22 On the student front, the intake process for second half 2020 has already captured candidates to fulfill all seats available, ensuring 100% of occupancy for the following semester. A 22% growth in our medical student base Over the first quarter of 2020, we reached 9.7 thousand students, already including the Unison Lucas acquisition concluded this month. In addition, we have seen a better collection when compared to the same period last year, showing an excellent approach for the second half renewal rate and cash generation. All in all, and considering the external scenario, a very positive dynamic for the rest of the year. I also would like to highlight that considering all acquisitions we have completed, our total medical seats per year reached 1,866 seats, what means 13.5 thousand students at maturation, an 11% CAGR in the medical student base until 2026. Moving to slide number six, we can see our unique positioning In the medical community, our social responsibility, and therefore we have played an important role in sharing knowledge with all institutions, physicians, students, and patients through the initiatives below.
5:44 Allow free temporary access of our digital platform, MedCell, being already accessed by more than 9,000 medical students at 32 public and private medical schools, which will be a great opportunity to expand our market share and potential growth. Provide free content through online courses and webinar weeks, which has been a success attracting a large number of participants to our platform. Donation of masks, clothes, and other personal protection equipment to help departments and hospitals in 13 cities where we operate medical schools. Now, with respect to actions we have undertaken for students, employees, and professors, we are currently operating our theoretical classes online for all students and reorganize the schedule of practical activities in order to avoid any significant impact on the academic calendar for the first semester of 2020.
6:39 It's important to highlight that the in-hospital internships for fifth and sixth year students have already resumed and will not impact the calendar. Most of our CAP corporate staff started to work from home and are keeping all activities up and running well. We are also providing a full package of social and health assistance to our employees and families to help them during the pandemic, including HR initiatives such as online psychological care, yoga classes, corporate training platforms, free lectures, and support for family professions replacement, and many others. Moving on to slide seven, we will discuss our revenue and intake process. Fortunately, our first quarter of 2020 We have already completed the enrollment process with 100% of frequency as expected. And as we look ahead, we are currently seeing a strong demand for new applications for following semesters that will allow us to fulfill 100% of our medical fees.
7:55 We have kept our commitment to our professors, maintaining all salaries during the pandemic, maintaining our supply contracts, and also offering a high-quality education to our students, our platform, and practical activities for the fifth and sixth year. We are seeing a positive impact on the cash collection during this period, The delink simulation by April 2020 is 400 bits below the same period last year, reflecting our process improvements implemented last semester. Lastly, regarding revenue recognition, taking into consideration the interruption of home campus activities and that a significant portion of non-practical educational activities being temporarily offered through companies' online platforms, we expect that some practical classes will have to be replaced during the second half.
8:50 postponing the Ragnar recognition proportionally. Those effects were already considered in our first half 2020 guidance, indicated by the Natural Agro Guidance Range, which already contemplated that certain amount of practical class would be delivered in the second half. Next, turning to page number eight. After solid balance sheet and strong cash position put us in a health position with a competitive advantage to navigate these uncertain times. As you can see, we ended the quarter with 1.3 billion in cash position, raised essentially from the IPO and follow-on transactions. And with a limited debt, our cash flow is robust with an 81% conversion rate and a lower delinquency rate when compared to the same period last year.
9:41 Last but not least, Our cash flow keeps being strengthened by the synergy raised from M&A integration. We have been efficient in all integrations, leveraged our operational margins considerably. Given the high predictability of our business model, I'm confident in our ability to generate meaningful cash flow, which, combined with the strength of our balance sheet, will sustain financial stability regardless of the economic trend and enable us to continue to keep our growth strike. Moving next to our discussion of M&A and our integration process on slide 9, we achieved our position as the leading medical education company in Brazil partially through acquisitions. We have completed acquisitions over the past two years and added over 400 teeth in less than one year, or approximately 40% of our three-year target of 1,000 teeth.
10:38 We currently have more than 500 seats covered under MOU contracts. M&A remains a key pillar of our growth strategy and we continue to evaluate opportunities to deploy capital into strategic acquisitions across medical school seats as well as digital platforms that can add services and value to our students. Our financial strength and Cashflow Generation Capability afford us flexibility and we intend to remain opportunistic. Stepping back for a moment, we have outlined the stages that acquired companies go through before we start to see the synergies and margin contributions. Immediately, we guarantee 100% of the occupancy of all seats available.
11:24 Then, we begin to streamline discounts and to increase tuition after the implementation of our new curriculum. After, we migrate all transactions and administrative activities to ATIA's shared services to extract G&A efficiencies. Lastly, we implement ATIA's careers plan to fully integrate and reap the benefits from the acquired company. Importantly, the current operating environment has not slowed our integration process with recent acquisitions. We just finished integrating EPMED and we are moving with UniNovaSat and MedCell even during the pandemic. Now on page 10, you can see our successful acquisition track record and how we have been able to extract synergy faster. The regular expansion of margin gains has been significant across all acquired companies.
12:15 As we integrated and gained further scale, we have been able to see value creation margin improvements higher and faster than we expected in all acquired institutions. Even considering the more recent acquisitions, Concluded in 2019, such as IPEC and FASA, we can see a strong growth in operational leverage in less than one year. This solid track record shows our capacity to deploy capital into strategic acquisitions to create great return to our shareholders. Now, I will turn the call over to Julio that will show how the digital transformation accelerated by the COVID-19 crisis is changing the application process and opening many opportunities for us. Thank you, Virgílio.
13:02 Moving next to our discussion of innovation and technology and how this is changing the education process in the next two slides. So starting on slide 11, all of us are seeing a rapid shift in digital transformation strategies. In an environment like this, the need for accessible solutions in all markets has become greater than ever, and we are proud that we are leading the way in the medical education segment. The current environment is leveraging our core digital competency with an efficient process to create large and scalable medical education materials utilizing different formats in one single, easy to use, and sticky platform.
13:47 Our cutting-edge platform can deliver a personalized learning experience for each student, including communication, learning, tutoring, and assessment tools. As an additional feature, we have just now launched our proprietary synchronous class capability to the experience we provide where our professors will be able to interact on a live environment with our students as an integrated piece of our methodology. On the content delivery side, we are proud to launch the second season of our instructional medical residency web series. With 12 new episodes, we added another 50 clinical cases where 15 of our professors are acting and performing, as well as 100 new video lessons covering these cases.
14:38 This is another important step of our edutainment strategy, delivering content in formats that are connected to the quality of the new generation of students and innovating as it is needed in our industry. The proprietary software and content development and adaptive learning technology allows us to offer a personalized learning experience for the student no matter where they are in their learning curve or career. This is critical for our solutions where we use the power of our data collection to help students to be more effective. Moving now to slide 12. Afia's core strategy is to combine quality medical education with intensive use of technology. We are committed to providing innovative technology solutions that assist our students as they spend more time online to work and study in this environment and later on.
15:40 Even prior to the rise of COVID-19, we have been very intentional on strategic planning for enhancing our digital offerings. The pandemic proved the efficiency of our digital platform as more than 90% of our undergrad medical students engage online with a positive feedback and acceptance. Over 93% of our graduate students mentioned they would recommend their online classes and course to a friend. With respect to other students as shown on these charts, These added digital products, content, and features consistently delivered increasing customer count growth during the quarter. Our monthly active users increased 17.5% from January to March to more than 16,000.
16:33 At the bottom of the first chart, you can see the current consumption of our content with over 2.4 million learning objects used by our students during the quarter. Adding to that, we see the monthly content consumption increasing more than 26% as we scale our tutoring system. Engaging more students to our platform is key to future conversion to our other products and services AFIA will be offering. The strategy is to build and nurture the relationship generating loyalty with students and other medical professionals. With the proven effectiveness of our digital platform and services, we have strengthened our position as the leading innovation and tech company in the Brazilian medical education segment. This shift in teaching and learning behavior is also giving us an opportunity to take further look at our long-term digital strategy.
17:34 While no one knows how long the current business environment will persist, It is our expectation that some of the programs and our processes put in place because of COVID-19 will continue over time. As a result, we are actively assessing our current product offerings as well as expanding our view to potential acquisitions. Our strategy is to further build our share and drive long-term profitable growth. Now, I'll turn the call over to Luis to discuss our financial results.
18:10 Thank you, Julio, and good morning, everyone. Before getting into the financial results, I'd like to add that it's a pleasure to be hosting my first call as AFIA CFO. As Virgílio said, it was certainly a very unique time that we are all living through. I'm particularly proud that we delivered a successful quarter that is tracking In line with our first half guidance, we are particularly pleased with the execution in the first quarter to quickly move all the classes online, which, in turn, enable us to report a good start of the year.
18:59 Moving to slide 14, my discussion will focus on the main and the most significant P&L items. There is additional info in the earning press release that you can refer for more information. And shown on this page, we had a very good quarter across all key metrics. We also reported higher margins. Let me highlight a few. We started with the medical seats and students, both of which saw a significant increase during the quarter. With respect to the number of medical school seats, we added 417 seats year-over-year for a total of 1,684 by quarter and a 32.9% increase over first quarter 2019.
20:01 Reflecting the seat maturation process, the number of students in the first quarter 2020 was 7,956, an increase of 58.8% over the same period of the prior year. Subsequent to the quarter end 2020, we added another 182 seats with the acquisition of Unison Lucas and with a potential website of further 106. As a reminder, considering the position of Unison Nucat, we have already made our full position as of today is 1,866 feet and 13,400 students, which leads us to 11% greater In student base, considering the period of 2019 until 2026.
21:12 Performa Net Revenue for the quarter was up 27.2% year-over-year to 272 million reais. Excluding the acquisition of UniHidempo, which closed in the end of January 2020, Performa Net Revenues grew by 20.1% year-over-year, reaching R$ 267 million. The increase was primarily driven by organic revenue growth, mainly due to maturation of medical school seats. The strong top-line growth, combined with cost decisions and result of synergy of strong acquisition was Reflected in our Performa Justa de Vidal Increasing 36% to 141 million reais And the margin expansion of 333 base points Excluding the consolidation of UNI-Redentor Performa Justa de Vidal Increased 33.3% year-over-year to 137.8 million reais and a margin increase of 530 base points. Adjusted net income was 131.7%,
22:42 reflecting the revenue contribution synergy captured in the margin expansion from consolidation of acquisitions. Our diluted earnings per share increased 54%, achieving R$1.09 per share. I'd like to remind you all that two types of stationality affect Acquia business as they fail in our earnings relief and as a result, in a typical year, the first quarter is normally the strongest in the terms of revenues, but not in terms of cash conversions since MedCell revenue recognition mostly happens on the first and the fourth quarters.
23:29 Moving on to page 15 for discussions of key operating metrics by business units. We delivered strong results in the first quarter as both business units continued performing very well. Growth in key operating metrics as shown on this slide is being driven by a combination of organic growth and acquisitions. Our average monthly medical tuition fees at the quarter ends were 8,235 reais, which was 8% above the same period in 2019.
24:15 This reflects a combination of new students enrolling with a higher tuition rate, combined with the students graduating with a lower tuition. As shown in the middle chart, 77% of our combined tuition fees are derived from medical schools. The combination of a 47% increase in the number of students and an 8% increase in average tickets resulted in a combined tuition fees of 59% when compared with the first quarter of 2019. With respect to B02, we had almost 12,000 active-state students at the quarter end, an increase of 22% over the same period last year.
25:14 We can see an increase of 29% and 22% in the number of students of craft course and CME for B2B and B2C respectively. Moving on in a deeper analysis of our revenue and EBITDA on slide 16. Our business model enables us to generate a higher predictable revenue growth. However, as mentioned previously, acquisitions are a key part of our growth strategy. And as shown on this page, we have provided net revenue and adjusted EBITDA bridges from our historical first quarter 2019 revenue to the reported first quarter 2020.
26:07 For the quarter, net revenues increased 88% to 272 million reais. Excluding the consolidation of Unirredentor, net revenue grew 78% in the quarter with a contribution of 84 million reais from acquisitions and R$ 28 million from organic growth, which is comprised of the maturation of the medical school seats and increase of average ticket. On the right side of this page, we show the first quarter of 2020 adjusted EBITDA. During the period, adjusted EBITDA increased 88% year-over-year to R$ 141 million.
27:00 Excluding the consolidation of UNHDP, adjusted EBITDA grew 84.4% with 47 million reais contributed from acquisitions and 16 million reais from organic growth. Aside from strong revenue growth, our results are also benefiting for the synergies that are being realized from acquisitions as You've already heard of Virgílio. Moving on to discussion of the cash flow on the slide 17. Cash is crucial in the current environment and we have a very strong and health balance sheet that strengthens even further by the follow-on offer we completed early this year.
27:56 These strengths of our balance sheet that will enable us to continue to grow to business and support future acquisitions. Cash and cash equivalents of 1.3 billion reais at the quarter end was up 960 million reais at the end of 2019, a 35% increase. The significant increase in cash compared to the year-end 2019 reflects strong generation cash flow and the proceeds from February 2020 follow on offer. The majority of the funds is invested in low-risk Brazilian reais denominated instruments.
28:46 The total debt was R$497 million at the Quarter end 2020, up from $361 million at the end of 2019, with increase related to the account payables to selling shareholders. This quarter debt is 47% current. Cash flow generation remained strong in the first quarter 2020, which results in a cash conversion rate of 18.7% compared to 82.7% in the first quarter 2019. This was a slightly lower cash conversion rate versus first quarter 2019, mainly due to the seasonality in the beginning too, associated with net sale business.
29:44 As I said in the beginning, revenues from our prep courses are recognized mainly in the first and the fourth quarter of each year, but receivables are mostly stable during the years. In this sense, net sales results negatively affect cash conversions in the first and the fourth quarters. Turning next for discussions about guidance on slide 18. As mentioned earlier in the presentation, our first quarter results were trending in line with our first half 2020 guidance. As a result, we are reaffirming our guidance provided during our year-end conference call.
30:36 As a reminder, the world is still amidst a pandemic. Economics are slowly opening up and Our guidance takes in account the best information available at this point of time. Two key metrics from the first half 2020 are as follows. The first half 2020 net revenues between 475 million reais and 510 million reais. The first half adjusted EBITDA margin Rending between 45% and 46.5% Our guidance includes the impacts of the adoption of IFRS 16 Includes UNHR 12 starting February 1, 2020 And excludes any other acquisitions that may be concluded after the issuance of this guidance I would point out the possibility that revenue recognition for some practical classes could be pushed to the second half of 2020 upon the resumption of the classes.
32:02 Summing up, please turn to the next page, slide 19. We operate in truly extraordinary times, times of great challenges, but also times in which we can see many key opportunities ahead. We are very confident in the strength, the resilience, and the overall health of our company. We are navigating in currency and circling well. Our leadership position is creating even more demand for our medical students. And as mentioned earlier, We are currently seeing demand for available seats ensuring we maintain our 100% occupancy.
32:56 The use of our digital platform is strengthening our brand and positioning and we see opportunities to expand this platform both organically and through acquisitions. Given the nature of our business coupled With the high demand for seeds, we have a model that presents us with a highly predictable organic growth given the maturation of the seeds with an expected CAGR of 11% in our student base from 2019 to 2026. We are maintaining our long-term strategic focus of which M&A is a key component.
33:45 We already have a solid pipeline and we are on track in generating synergies from acquisitions completed over the past two years. Integration is progressing even in the current environment. In turn, we anticipate further emerging expansions. Lastly, as you have heard through this presentation, We have a strong balance sheet and generated a significant cash flow. These attributes coupled with the actions we are taking now enable us to manage through the situation today while funding targets the strategic investments that will benefit us going forward.
34:37 This ends our prepared remarks. We are now ready to take your questions. Please open the lines for questions. Thank you, sir. As a reminder, to ask a question, you would need to press star 1 on your telephone. To withdraw your question, please press the pound key. Please stand by while we compile the Q&A roster. I show our first question comes from the line of Marcelo Santos from JP Morgan. Please go ahead.
35:08 Hi, good morning. Thanks for taking the question.
35:11 I have two, actually.
35:12 The first would be about the candidates that you already have for the intake of the next season. Could you just explain a bit more how does this work?
35:21 I mean, what kind of commitment do they already have? Are there still candidates or there are some that are already enrolled? Because you might have candidates that cannot pay in the end. So how confident you are that you'll get 100% occupancy Just could explore a little bit more on this. And the second, if you could discuss a bit the schedule for Greenfield opening. So you had two Greenfields that were supposed to be open in the first half, but given the COVID situation, this was the visit didn't happen as far as understood. So could we still expect this to open in the second half of the year or is it more prudent to expect everything for 2021? These are the two questions.
36:07 Hi, Marcelo. This is Virgílio. I think your first question here about the candidates that we have, and we understand there is enough to fulfill 100% of the seats. The ratio that we are seeing, the number of candidates applying for all seats in Brazil, when we have the comparison to the same semester, the last semester that we have, it's much more than we need to fulfill all new seats that we have to enroll for the following semester. So what we are doing, we actually right now have almost 80% of the enrollment already confirmed. We are just calling the students to fulfill all the seats. We anticipate a lot of the process because of that using MM grades results from previous years.
37:00 So that's the way that we are doing an alignment duration comparison for the last years and also anticipating the enrollment for the following semester. About your second question, how we are opening the greenfields, we have two. This is the very final step to have the signature from the Ministry of Education. That's the last step that is required. And we think that this signature can happen, we expect to have this by the end of the semester. But the truth is that the means of applications, everything stopped right now because of the pandemic.
37:45 And even if we have the beginning of this, the authorization to start our operation, we are just expect to have the beginning of this operation the second semester or maybe the beginning of 2021. That's I think one of the downside from the pandemic. to start the new sites, okay?
38:13 Okay, just to follow up on the first, so when you say 80% has already been confirmed, that means they have already paid something or some kind of initial fee. What does confirmation entail?
38:27 The students confirm the enrollment. They have to pay the first month's tuition. We still have some seats to fulfill, but we have candidates in the basket to convert them and have 100% of occupancy in the second semester. Remembering that the second semester volume of new students is lower than the first semester. So the ratio is higher than the volume of candidates that we have to fulfill all the seats. It's better than the first semester. Great. Very clear. Thanks a lot. Thank you. Our next question comes from the line of Susana Salaru from Itao.
39:13 Please go ahead.
39:16 Hi, good morning all. Thank you for taking our questions. Our first question is related to the margin expansion of the quarter. If you could elaborate a bit more what were the main drivers behind the cost savings and if you could also talk about what were the synergies that were unlocked from the acquisition. That would be our first question. And the second question is related to the tickets. We saw that the med school tickets went up significantly. If you could just comment how was the trend of the healthcare as medical school trend for the tickets and also for the other courses that you had. Thank you.
40:00 Hi, Susana. This is Virgílio. About the margin expansion, I think it's three main drivers that is driving all this efficiency that we are getting from our operation. First is the scale. We are seeing all this maturation in all corporate activities, All the expenses we are diluting time over time and that will be a strong trend as we still have the maturation until 2022. Second, as we are seeing on these acquired institutions, we are having a lot of synergies and faculty costs.
40:48 We start implementing our curriculum, maximizing the number of students that and many more. We also have a study in groups per professor, so we minimize the hour rate per student and also improving the quality of all these practical classes. So this is 50% of the costs. So when we have some change on that, after implementing the new curriculum, it's something that's very strong in terms of synergy and leverage operation. And third, after integration, full integration, and we pull all activities to our shared services, we have all the GMA efficiency. We have a very well implemented process in our back office here. So when we push all the transaction activities, academic back office, HR, payroll, supply chain, IT activities, We didn't change any FTE full-time equivalent on our back-office operations.
41:50 So this is the three main drivers. Remembering in the top line, the first initiative as a quick win for all institutions that we acquired to guarantee 100% of occupancy. Most of the institutions that we are plugging into operation after a closing acquisition, they are not using 100%. They are not maximizing the students. If they have some dropouts in the middle of the program, they are not replacing the student in the beginning. So that was the main drivers. for all this 500-bit expansion that we have seen quarter over quarter. Luis will help me to explain the second question about the average ticket.
42:36 Hi Susana, it's Luis speaking. About the ticket that we saw increase from this quarter regarding the quarter in the last year, The ticket dynamic is related to the maturation of our business. We had in 2017 a ticket increase for the first year only. Since then, we have an increase of the tickets because these students begin with a higher ticket and the lower tickets of the students are being graduated. So, during the maturation, the ticket increases by itself. So, that's why we are having an increase in our tickets.
43:31 Susana, just adding one point that is important. Besides all this maturation, when we changed our curriculum back in 2017 and we have this recurring positive effect on the mix of our tuition, we also have this Just a reminder, Unirredentor that we started operating back in February, this asset has the highest tuition in ASEAN, around 10,000 reais. So also you have this positive effect when you have more months and also maturing when you hit into operations. So this is what we are doing as a strategy semester over semester.
44:20 We are just changing prices related to inflation. The exception is when we have a new acquisition or we Julio Eduardo Razente de Angeli, Virgílio Deloy Capobianco Gibbon, Julio Eduardo Razente de Angeli, Virgílio Deloy Capobianco We are requiring the medical school tuition.
45:08 Perfect, perfect. Thank you. Thank you. As a reminder, to ask a question, you will need to press star 1 on your telephone. To withdraw your question, press the pound key. I assure our next question comes from the line of Chargo Botoleschi from Goldman Sachs. Please go ahead. If you have your phone on mute, please unmute your line. Okay, our next question comes from the line of Vincious Romero from UBS. Please go ahead.
45:53 Hey guys, good afternoon. Hope everyone is fine. So two questions on our side. The first on the platform that you guys mentioned and Julio gave us a little bit more of detail. Just a question here. Given that the product is being pretty well received, what would you guys need for this platform to become a new revenue stream? Do you have any idea what would be the economics for that for offering for other medical schools? Do you want to do that? And the second question is also related to business unit two. Just to confirm here, if you are seeing some difference in terms of the demand dynamics for the Business Unit 2, both on MedCell and IPMED. That's it.
46:37 Thanks, guys.
46:43 Yeah, sure. Both? Yeah, I'm sorry. So the first question is on the MedCell platform. If you guys could elaborate a little bit on what would you need for this platform to become a new product, a new revenue stream by offering it to other institutions. And if you guys have any idea of what will be the economics. Did you guys understand?
47:17 Yes. And the next one?
47:20 And the next one is just also on the business unit too. Just if you're seeing any difference in terms of as far as demand goes, if the demand is so resilient as it is on the business unit one.
47:37 Okay, hey, this is Julio, and hello everyone, hope everyone is safe out there as well. So for the first question, first, I mean, we already have in place a team working on the B2B side of the business, so we already have a, it's small, but still, I mean, it's revenue coming for B2B, What we have today, what we are offering to these schools basically is the solution for the last year for the internship program. So what happened especially now with all this situation is we offered the platform for the schools that they didn't have anything actually to offer to the students and we had 32, imagine that there are around 340 medical schools in the country.
48:36 Out of those 32, 40% of those are public schools. So we see the need, you know, due to the situation and the idea in terms of what needs to become a revenue stream, as you said. I mean, we're charging these, actually the current clients that we have on a subscription-based model. So the idea is to convert these schools especially those ones that are private into customers so you know we're working with them as we speak here and as well I mean the other ones the public ones you know tricky to find a commercial agreement but you know we can obviously work on the B2C side with those students. But remember, you know, when the way we see this is that on the thesis of AFIA, we want more of these students engaging in a platform.
49:38 And as much, you know, collecting the information, we can extract revenue from another institution. And further on during their career, you know, the idea is to keep offering other and many other solutions, you know, in continuing medical education, in graduate business. So this is the idea. But the way it works is, you know, it's a subscription-based model today. And in terms of the second questions on the demand, especially for bed cells, I mean, it's still an interesting, very good demand. This year, specifically, there's the The Revalida exam, which is the test that students that are studying medicine in other countries, they will have this test on October 11th this year.
50:33 So there's a significant amount of students that couldn't take the test since 2017. So there's a strong demand there. And again, I mean, for test prep, still, I mean, this business is growing in terms of market You know, around 20% a year. For the graduate business, we still see the demand. The only thing is that since we're selling this to doctors, so the situation now is that these doctors, of course, they're focused on COVID. You know, some of their offices, you know, they're not, you know, working. So what we are seeing is that they're postponing a bit the decision.
51:20 but that's why when I sat on my part of the presentation, we are reviewing the portfolio especially working with more of the online content for the graduate business as well. We launched a couple of courses for free and the last one which is quite interesting is one of a, it's a therapeutical update with telemedicine. So we are offering this course for our graduate students, and we see significant demand there. And that will be tied to our product offers that we have today in the portfolio. So, you know, we're shifting more to be online, and you'll probably see a lot of progress on that front using, again, our technology.
52:16 Very clear, Julio. Thanks. Thank you. I share our next question. It comes from the line of Emma Sgaz from Goldman Sachs. Please go ahead.
52:28 Yes, hi. Thank you for taking my question. First of all, thanks, Virgílio and team, for the presentation, and congrats for the results. We have two quick questions. First is a follow-up from Susana. and I apologize if I missed part of it we got temporarily disconnected from the call but I just wanted to go back to the pricing question for new intakes the freshmen that are coming in now could you just from what I understood you're adjusting just by inflation for the medical students and then I wanted to confirm first wanted to confirm that and for non-medical students what's the is that also in line with inflation or what should we expect there? Again, this is about the intakes, the new classes, not existing students.
53:18 And if you've generally in the market, if you've seen for medicine, we know that the demand dynamics are obviously absolutely different than from other courses. But have you just seen, given that people are going through different economic challenges, have you just seen as medical schools are preparing on the private side, are preparing for the new intakes, Have you seen more promotions or discounts, or would you say this is not something that you've seen in the market so far? Thank you.
53:51 Okay, Irma. Thanks for the question. First, the maturation of the average age for medical students is twofold. We have changed the prices for new students in the beginning of the year, close to inflation. So our average ticket for new freshmen is around 8,000 reais per month. And as we have this changing tuition in the past, when we implemented new curriculum back in 2017, 2018 for the new acquisition, We have the maturation effect because when we acquired, the average ratio was 5,000, 6,000 reais, we changed 7.5, 8,000 reais, so we have the maturation of these students moving to the following semester, so that's why we'll have this positive recurring effect in 2026 when we have the full maturation.
54:58 About the other programs, we are also changing So, as we can expect from modeling proposal, we are also seeing other programs for undergrad varying close to inflation year over year. What we are seeing that also on this progress we are seeing above inflation is the mixed effect because problems that doesn't make sense to offer in some regions After Acquisition. We are closing this program and we are not going to fight against any other play or distance learning. We are completely focused on health and other medical and other health programs.
55:43 About the payment capacity of our students, one indicator that is much better than we expected previously is the cash collection. When you compare month by month against 2019, we are three or four percentage points in all institutions better. What is happening? We changed a lot the collection process. We implemented a lot of new procedures, new controls that helped a lot renewing all these students for the first semester of 2020. So this positive effect, even considering the economic difficulties from the COVID-19 We are seeing a very positive low-hanging fruit that we have on this front.
56:39 What we are doing for the renewal is in a case-by-case situation, we are offering a financial aid for these families. And in the market overall, from the competitive dynamics within medical schools in the private sector? As an option on our relief, we already have candidates to fulfill 100% of our seats, so the ratio of candidates for seats is very healthy that we can keep guaranteeing 100% of occupants even considering this external scenario.
57:40 We have already enrolled 70% of the student base for the new students, already paid the July tuition.
57:48 Perfect.
57:50 Okay.
57:52 Perfect. Thank you. Thank you. And our last question comes from the line of Scott Piper from Itaú. Please go ahead.
58:03 Yeah. Hi. Apologies if previously asked, but I was wondering if you could give us some color on the economics of future M&A prior to the COVID crisis. The price per student for acquisitions was starting to gravitate higher given increased competition and I'm curious how you see that development both now and going forward given the crisis and what you're at, you know, the dynamics of accretion for potential future acquisitions and most importantly How your appetite has changed because of the crisis for acquisitions going forward. Intuitively, you would think that the environment would be better for acquisitions given your cash situation and probably more strain in the economy, but I was just wondering if you could elaborate on that.
59:14 Okay, Scott. So our M&A pipeline, it's moving very, very fast. We have already more than 500 teams that we analyze under MOU contract. We didn't slow the pace that we are analyzing assets. Actually, as a kind of deposit, we are seeing much more opportunities coming to the table. I think small players, medical schools, they are getting concerned how they can continue to isolate and keep confirming 100% of their enrollment. So it's a kind of opportunity that we have to reanalyze and try to have a better negotiation in terms of price in the paraffin.
1:00:11 So we are not guiding any We have completed different valuations and all of them deliver incredible rate of return. As an example, we have a green field of impact that the number of the value per student is completely different from that was EBITDA multiple because they have a very large operation, many programs in the portfolio and a positive EBITDA. So the way that we analyze is a multiple EBITDA for more mature and Complete Institution. And when they have some maturation and also almost a greenfield license that we are buying, that will be much more related to multiple per student, per seat, I'm sorry.
1:01:16 So just about our archetypes, we are keeping the integration at a very fast pace, even considering the isolation that we have in some cities. We are doing a very well process. Of course, to conclude and to close an acquisition, we have to take care that all this process and also we have to close and have all the accounting procedures, the external audits to report this new acquisition. So we are having some kind of flow. and other new orders that we can acquire and close two or three acquisitions per quarter. So that's something that we are putting our order much more concerned in our capacity to integrate and have the condition to have all the procedures to Our balance sheet approved on a quarterly basis, considering that we have to operate in a distance for one or two months already.
1:02:25 But we are not slowing the pace. That's, I think, is the main message here. Okay, thank you.
1:02:33 Yes, Scott, it's Luis speaking right now. If I could add something, additional points to give to you, that's very interesting to highlight that In this crisis, we see opportunities in digital platforms to add more service in this moment. What we saw in this crisis with MedCell business, we saw very, very strengths on that, on digital transformation. So in this case, on these digital platforms, we are even speeding up Thank you. I show no further questions in the queue.
1:03:19 At this time, I'd like to turn the call over to Virgílio Gibbon, CEO, for closing remarks. Please go ahead.
1:03:46 So thank you, thank you all. To conclude my remarks, I'd like to reinforce our business resilience and outstanding dedication of our team to deliver this great first quarter results. We have firm our first half 2020 guidance even under COVID-19 crisis. We are operating in unusual times, times of great challenges and uncertainty, but also times at which we can differentiate ourselves and see many key opportunities for ATIA. Thank you for joining us today and we look forward to meet you when all the situation is over. Keep safe. Bye bye. Ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.
Follow Afya Limited into a list and get an email when it puts out news.
Head of Investor Relations
Chief Executive Officer
VP of Innovation and Continuum Medical Education
Chief Financial Officer
Analyst, UBS
Analyst, Goldman Sachs
Analyst, Itaú